RT Journal Article
SR Electronic
T1 Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2597
OP 2603
DO 10.21873/anticanres.15039
VO 41
IS 5
A1 DANIEL KREJCI
A1 PETR OPALKA
A1 JANA KREJCI
A1 MILADA ZEMANOVA
A1 PETRA ZEMANOVA
A1 JURAJ KULTAN
A1 ONDREJ FISCHER
A1 JANA SKRICKOVA
A1 MONIKA BRATOVA
A1 MARKETA CERNOVSKA
A1 MICHAL HRNCIARIK
A1 HELENA COUPKOVA
A1 KAROLINA HURDALKOVA
A1 MAGDA BARINOVA
A1 LEONA KOUBKOVA
A1 DANIEL DOLEZAL
A1 MARTIN SAFANDA
A1 MILOS PESEK
A1 MARTIN SVATON
YR 2021
UL http://ar.iiarjournals.org/content/41/5/2597.abstract
AB Background/Aim: Platinum-based chemotherapy with pemetrexed or paclitaxel/bevacizumab are regimens used in combination with checkpoint inhibitors in non-squamous non-small cell lung cancer (NSCLC) treatment. We conducted a real-world study to compare the outcomes of these chemotherapeutic regimens. Patients and Methods: We investigated 1,534 patients with advanced non-squamous NSCLC treated with platin/pemetrexed (n=1212) or platin/paclitaxel/bevacizumab (n=322) in 9 cancer centres in the Czech Republic. Results: The regimen containing platin/paclitaxel/bevacizumab showed significantly better overall response rate (ORR) compared to the platin/pemetrexed [40.8% vs. 32.7% (p=0.008)] in the overall population and [55.0% vs. 38.8% (p=0.002)] in the Eastern Cooperative Oncology Group performance status 0 group. There was no significant improvement in progression-free survival (PFS) and overall survival (OS) in either of these two groups of patients. Conclusion: In our real-world data analysis, patients treated with platin/paclitaxel/bevacizumab had better overall response rate (ORR), but not PFS or OS. Thus, both treatment regimens are similarly effective. Their selection should therefore be based on the potential side effects.